Related Experiment Video
Updated: Jul 23, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Clinical classification of pulmonary hypertension
1University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Pulmonary hypertension, a common disease, has seen evolving classifications. A new clinical approach aids in prevention and treatment, reflecting recent medical and surgical advances.
Area of Science:
- Cardiology
- Pulmonology
- Pathophysiology
Background:
- Pulmonary hypertension (PH) is a widespread condition with diverse causes.
- Previous classification systems, primarily based on autopsy morphology, have had limited success.
- Advances in PH treatment and prevention necessitate a revised classification.
Purpose of the Study:
- To trace the historical development of understanding pulmonary hypertension.
- To introduce a new clinical classification for pulmonary hypertensive diseases.
- To align classification with current and future treatment and prevention strategies.
Main Methods:
- Review of historical literature on pulmonary hypertension nomenclature and classification.
- Analysis of recent advancements in medical and surgical interventions for PH.
- Development of a clinically oriented classification system.
Main Results:
- Past classification efforts based on morphology proved insufficient.
- Recent therapeutic progress highlights the need for a functional classification.
- A new clinical classification is proposed, integrating etiological and therapeutic insights.
Conclusions:
- The evolution of understanding PH has led to a more practical clinical classification.
- This new classification facilitates targeted prevention and treatment strategies.
- It supports the integration of recent medical and surgical advances in managing PH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Heart Failure IV: Classification and Diagnostic Evaluation
Hypertension I: Introduction

